Welcome to the latest issue of Pharmaceutical Technology Focus magazine

In this issue, we report on the evolving story around drug shortages. The cover story investigates how recent quality issues and an increasingly limited generic drug manufacturing landscape have aggravated shortages, especially for cancer drugs. This has led to clinicians adopting rationing strategies. This issue’s big interview further delves into strategies to manage medical care in the midst of these shortages.

Also this month, we use data to explore how market access to drugs for rare diseases differs across the world. Nonprofits, which facilitate access, and each country’s unique drug reimbursement framework, dictate how soon patients can access these highly specialized and expensive therapies.

Don’t miss the special thematic supplement on how artificial intelligence tools are being used in the pharma and healthcare sector. All this, with the latest news, analysis and data on the pharmaceutical and biotech industry.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This content was updated on 25 January 2024